Conflicting HOPE-3 analyses divide FDA panel over deramiocel in Duchenne muscular dystrophy
FDA advisers voted 9 to 3 against deramiocel’s Duchenne cardiomyopathy evidence after challenging the Phase 3 analysis and trial population.
Pharma & Biotech